An observational study in IBD (Inflammatory Bowel Disease), sponsored by Viome. Recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-15.
Sponsored by Viome · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Inflammatory Bowel Diseases with a site in Brazil — 8 open to participants now, 9 under way, 4 of them phase 3. Inflammatory Bowel Diseases · Brazil.
Among the 19 studies in Inflammatory Bowel Diseases with a site in Brazil, this one is one of 2 that started in 2025, is one of 2 observational ones, and was the 17th registered.
1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.
Browse Inflammatory Bowel Diseases studies →8 of the 19 studies in Inflammatory Bowel Diseases with a site in Brazil are open now. Recruiting first, the newest first:
Spyre Therapeutics, Inc. · Sites in Brazil, United States, Argentina and 33 more countries
Ages 18–75
Xencor, Inc. · Sites in Brazil, United States, Argentina and 16 more countries
Ages 18–75 · Healthy volunteers
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · Sites in Brazil, United States, Australia and 25 more countries
Ages 18–85
Eli Lilly and Company · Sites in Brazil, United States, Austria and 13 more countries
Ages 2–17
Janssen Research & Development, LLC · Sites in Brazil, United States, Australia and 14 more countries
Ages 2–17
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 9
First in 2005; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 140 across 626 observational studies indexed under Inflammatory Bowel Diseases.
Median enrollment 307 across the 17 interventional studies, 254 across the 2 observational. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 19 have an industry lead sponsor. The 10 most frequent:
Viome is the lead sponsor of 25 studies on the registry; 13 are open to participants now.
Viome has 1 study filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
2 of the studies in Inflammatory Bowel Diseases with a site in Brazil that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
| NCT07012395Spyre Therapeutics, Inc.A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies in Inflammatory Bowel Diseases with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will collect longitudinal biological samples and survey data to identify the triggers of IBD flares.
This is a longitudinal observational study whose goals are to identify:
Microbial and human molecular triggers of IBD relapses, Microbial and human molecular pathways strongly associated with flares that could be targeted with nutrition with a therapeutic potential, Biomarkers of IBD for Dx purposes, Identify microbial functions associated with release of BH4.
Adults diagnosed with Crohn's Disease or Ulcerative Colitis that are patients at Universidade Federal de Santa Catarina (UFSC) Hospital and under care of Dr. Vivian Menegassi
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Individuals diagnosed with IBD
Stool microbial KEGG orthologs (KOs) associated with IBD
Metatranscriptomic tests will be used to quantify microbial KOs in stool samples. At the end of the study, we will use machine learning to identify KOs whose expression is associated with IBD.
Time frame: For 12 months from enrollment
Started Jan 2025 (actual). Primary completion is estimated for Feb 2030, 61 months after the start.
Of 37 industry-sponsored observational studies under Inflammatory Bowel Diseases, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 44. This study's planned 61 months is above that.
Counting every sponsor, half of 281 studies reached it within 36 months; a quarter within 20 and three quarters within 122.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.